Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

15.9%

7 terminated/withdrawn out of 44 trials

Success Rate

78.1%

-8.4% vs industry average

Late-Stage Pipeline

50%

22 trials in Phase 3/4

Results Transparency

88%

22 of 25 completed trials have results

Key Signals

4 recruiting22 with results

Enrollment Performance

Analytics

Phase 4

17(41.5%)

Phase 2

13(31.7%)

Phase 3

5(12.2%)

Early Phase 1

3(7.3%)

Phase 1

2(4.9%)

N/A

1(2.4%)

41Total

Phase 4(17)

Phase 2(13)

Phase 3(5)

Early Phase 1(3)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (44)

Showing 20 of 44 trials

NCT04838288Phase 4Completed

Cognitive Outcomes in Stable Renal Transplant Patients Switched fromTacrolimus to Envarsus XR™

Role: collaborator

NCT03841097Phase 4Active Not Recruiting

Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants

Role: collaborator

NCT03769298Phase 2Recruiting

CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients

Role: collaborator

NCT03321656Phase 2Recruiting

Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

Role: collaborator

NCT06751992Phase 4Recruiting

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

Role: collaborator

NCT03979365Phase 4Completed

Envarsus XR Compared to Immediate Release Tacrolimus

Role: collaborator

NCT07290777Phase 2Not Yet Recruiting

VEL-101 to Prevent Rejection After Kidney Transplantation

Role: lead

NCT04773392Phase 4Terminated

Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

Role: collaborator

NCT03461445Phase 4Completed

Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients

Role: collaborator

NCT03823768Phase 4Completed

Envarsus Neurotoxicity Burden in Liver Transplant Patients

Role: collaborator

NCT04665310Phase 4Active Not Recruiting

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

Role: collaborator

NCT04469842Early Phase 1Recruiting

Early Use of Long-acting Tacrolimus in Lung Transplant Recipients

Role: collaborator

NCT03555448Phase 4Terminated

Once Daily Immunosuppression Regimen

Role: collaborator

NCT03410654Early Phase 1Completed

Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.

Role: collaborator

NCT05251727Phase 1Terminated

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Role: lead

NCT04711291Not ApplicableWithdrawn

Efficacy of Envarsus XR and Digital Health Technology in Reducing Tacrolimus Fluctuation and Frequency of Dose Changes

Role: collaborator

NCT03511560Phase 4Completed

Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation

Role: collaborator

NCT04225988Phase 4Completed

Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients

Role: collaborator

NCT05238493Phase 1Completed

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Role: lead

NCT03760263Phase 4Completed

Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus

Role: collaborator